Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Summary

This phase II trial is studying how well selumetinib works in treating patients with recurrent or persistent endometrial cancer that has come back or is persistent. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2009-09

Primary completion

2016-01

Completion

2016-01

Outcome

Missed primary endpoint

paper Selumetinib was tolerable in this population but did not meet pre-trial specifications for clinical efficacy. PMID 25887099 ↗

Publications

• Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul;138(1):30-5. doi: 10.1016/j.ygyno.2015.04.005. Epub 2015 Apr 14.

Drugs

Indications